Microfat vs Nanofat: The Real Difference

Most training teaches that microfat and nanofat are two grades of the same material — one just finer than the other, like settings on a dial. I argued the opposite in a peer-reviewed clinical review: they're two distinct therapies, separated by a single variable. Get this wrong and you'll inject the right preparation into the wrong plane. Get it right and the choice becomes a controlled clinical decision.

Microfat and nanofat are not two grades of one material — they're two different therapies produced from one harvest, separated by parcel size. Microfat is purified and resized to roughly 500–700 microns: intact, living fat cells that add structural volume and are placed deep. Nanofat is emulsified further until most intact fat cells are destroyed: it adds almost no volume but concentrates regenerative cells, and it's placed superficially to improve skin quality. Different mechanism, different plane, different definition of success.

*This is general educational guidance from the published literature, not a clinical protocol to apply without proper hands-on training.*

Here's the distinction at a glance:

Because parcel size decides whether grafted fat survives. The moment fat is harvested, every parcel loses its blood supply and survives only on diffusion until new capillaries grow in — and diffusion works over very short distances. In a large parcel, the cells in the center sit too far from the surface and die, which is the origin of the oil cysts and unpredictable volume loss that gave early fat grafting its bad reputation. Smaller parcels have a greater surface-area-to-volume ratio, so every cell sits closer to the vascularized bed and the graft survives more reliably.

That's why microfat exists at 500–700 microns: small enough to revascularize fast, large enough to still contain the living fat cells whose survival is the entire point. The colleague who "tried fat transfer and found it unreliable" was usually using a large-parcel technique — failing not at fat transfer, but at parcel control.

One processing continuum. Raw lipoaspirate is purified — decanted, washed, gently low-speed centrifuged — to remove blood, oil, and fluid (aggressive centrifugation ruptures cells, so the technique stays gentle). The mechanics can run through several systems — a centrifuge, or a closed mechanical-emulsification kit like the Tulip nanofat sets many injectors learn on — but the system is just the tool. The parcel-size endpoint, not the brand, is what defines the product you end up with. Resized to 500–700 microns, it becomes microfat, the structural volumizer. Driven further by mechanical emulsification until most intact fat cells are disrupted, the same tissue becomes nanofat: an injectate enriched in the stromal vascular fraction — adipose-derived stromal cells and the regenerative signals they carry. You're not choosing between two products on a shelf. You're choosing where to stop one process.

Their mechanisms put them in different planes:

Put nanofat deep and you waste its mechanism. Put microfat superficial and you strand survival-dependent parcels in a plane too thin to support them. The deep-to-superficial technique experienced injectors use isn't convention — it's parcel size expressed anatomically.

Is microfat permanent? The fat that survives and revascularizes integrates and behaves like your own native tissue, so well-processed microfat is durable. Not every parcel survives, and retention varies by patient and technique, so "long-lasting when done well" is the honest framing, not "guaranteed permanent."

Is nanofat permanent? No — and that's by design. Nanofat adds no structural volume to make permanent. Its value is a regenerative, skin-quality effect that builds over time as the tissue responds, not a volume result you'd measure for longevity.

"Nanofat" is a size misnomer. Its particles are micron-scale, not nanometer-scale. The shorthand you'll sometimes see in training decks — "nanofat is sub-micron" or "under 600 nanometers" — is biologically wrong and shouldn't be repeated to patients or colleagues. What defines nanofat is a *processing endpoint*: emulsified far enough to disrupt intact fat cells and concentrate the regenerative fraction. Naming it by that endpoint keeps your reasoning anchored to the mechanism that actually operates.

Because it's the difference between performing a procedure you understand and performing one you memorized. If you can reason about parcel size, you can adapt to a case you haven't seen. If you only learned one device setting, you're stuck the moment the patient or indication doesn't match the slide. That reasoning is what real fat transfer training teaches — and what I've published on, so it's anchored to evidence, not a sales script.

[See what full fat transfer training covers →](/fat-transfer-training-for-nps-and-injectors) or [map your starting point →](/find-your-starting-point).